

Creating Additional Impact on Estrogen Receptor–Positive Advanced Breast Cancer

The Role of Combination Treatment Strategies

Thursday, 7 May 2015
12.00–13.00
Silver Hall

Chair and Moderator

Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, Belgium

Faculty

David Cameron, MD, FRCP
University of Edinburgh
Edinburgh, United Kingdom

Angelo Di Leo, MD, PhD
Istituto Toscano Tumori
Hospital of Prato
Prato, Italy

Peter Schmid, MD, PhD, FRCP
Barts Cancer Institute
Queen Mary University of London
London, United Kingdom

Target Audience

This educational activity is intended for medical oncologists, radiation oncologist, surgeons, and other healthcare professionals involved in the treatment of patients with advanced breast cancer, as well as translation scientists involved in research into targeted therapies for the treatment of these patients.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.



Agenda

- 12.00 Welcome and introduction
Martine Piccart, MD, PhD
- 12.02 Breaking down the pathways leading to endocrine resistance
Angelo Di Leo, MD, PhD
- 12.17 Q&A
- 12.20 Debate—"This house believes contemporary molecular information will be required for the maximum impact of treatments for metastatic breast cancer"
Moderator: Martine Piccart, MD, PhD
For the motion: Peter Schmid, MD, PhD, FRCP
Against the motion: David Cameron, MD, FRCP
- 12.40 Adding power to endocrine therapy in estrogen receptor–positive advanced breast cancer
Martine Piccart, MD, PhD
- 12.55 Q&A
- 12.58 Symposium prIME Points™
Martine Piccart, MD, PhD
- 13.00 Adjourn

